Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.81
-1.7%		$36.01
$28.25
▼
$60.08
$1.52B0.42245,859 shs407,386 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.31
-0.1%		$25.93
$18.80
▼
$36.46
$1.45B0.252.26 million shs2.22 million shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$28.99
-3.8%		$42.05
$23.75
▼
$52.93
$1.45B1.22476,064 shs309,976 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
▼
$6.65
$381.02M0.93.78 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-2.27%+0.65%+5.08%+13.29%+2.86%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+0.11%+45.11%+43.34%+45.34%+62.64%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-1.63%-6.34%-30.88%-27.28%+13.77%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.81
-1.7%		$36.01
$28.25
▼
$60.08
$1.52B0.42245,859 shs407,386 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.31
-0.1%		$25.93
$18.80
▼
$36.46
$1.45B0.252.26 million shs2.22 million shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$28.99
-3.8%		$42.05
$23.75
▼
$52.93
$1.45B1.22476,064 shs309,976 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
▼
$6.65
$381.02M0.93.78 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-2.27%+0.65%+5.08%+13.29%+2.86%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+0.11%+45.11%+43.34%+45.34%+62.64%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-1.63%-6.34%-30.88%-27.28%+13.77%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.75
Moderate Buy$47.6729.49% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.00
Hold$33.33-8.20% Downside
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
3.00
Buy$66.11128.05% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RVNC, PAHC, PCRX, and RAPP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$31.00 ➝ $36.50
10/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Perform$25.00 ➝ $36.50
10/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$38.00 ➝ $36.50
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D+) ➝ Hold (C-)
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeUnderweight ➝ Neutral$36.50
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$36.00
10/8/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold
10/7/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$30.00 ➝ $31.00
10/6/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$65.00
10/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$65.00
10/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$65.00
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.52B0.98$4.50 per share8.18$9.50 per share3.87
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.99$3.85 per share9.42$16.11 per share2.25
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$10.17 per shareN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$99.72M$2.4411.669.661.086.57%37.86%9.18%11/4/2026 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.3523.3015.32N/A1.96%9.68%5.30%11/5/2026 (Estimated)
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$111.48M-$3.04N/AN/AN/AN/A-29.02%-27.37%11/5/2026 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%N/A

Latest RVNC, PAHC, PCRX, and RAPP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.7320N/AN/AN/A$182.87 millionN/A
11/5/2026Q3 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$1.21N/AN/AN/AN/AN/A
11/4/2026Q1 2027
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.7630N/AN/AN/A$381.75 millionN/A
8/26/2026Q4 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.7130$0.85+$0.1370$0.53$381.18 million$396.75 million
8/5/2026Q2 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$1.12-$1.19-$0.07-$1.19$2.22 millionN/A
8/4/2026Q2 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.6460$0.73+$0.0840$0.12$191.06 million$192.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.30%N/A19.67%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A

Latest RVNC, PAHC, PCRX, and RAPP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.2%9/2/20269/2/20269/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.84
2.96
1.27
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.54
5.04
3.94
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
15.72
15.72
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05

Institutional Ownership

CompanyInstitutional Ownership
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%

Insider Ownership

CompanyInsider Ownership
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
48.47%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
12.48%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,60540.60 million20.92 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
82939.86 million37.31 millionOptionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
8447.98 million41.99 millionN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionNo Data

Recent News About These Companies

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/09/3147408/0/en/revance-alert-bragar-eagel-squire-p-c-is-investigating-revance-therapeutics-inc-on-behalf-of-long-term-stockholders-and-encourages-investors-to-contact-the-firm.html
Revance Names New CEO to Drive Next Phase in Aesthetic Innovation
May 23, 2025  |  globalcosmeticsnews.comG
Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation
May 21, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/revance-announces-leadership-succession-plan-200000684.html
Crown Laboratories Now Operates Under the Name Revance
March 31, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/crown-laboratories-now-operates-under-135900632.html
Johnson City-based Crown Labs now operating as ‘Revance’
March 31, 2025  |  wjhl.comW
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3038722/0/en/revance-alert-bragar-eagel-squire-p-c-is-investigating-revance-therapeutics-inc-on-behalf-of-long-term-stockholders-and-encourages-investors-to-contact-the-firm.html
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
March 4, 2025  |  accessnewswire.comA
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
March 4, 2025  |  accessnewswire.comA
RVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
March 4, 2025  |  accessnewswire.comA
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
March 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/04/3036820/3080/en/contact-levi-korsinsky-by-march-4-2025-deadline-to-join-class-action-against-revance-therapeutics-inc-rvnc.html
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
March 4, 2025  |  accessnewswire.comA
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
March 4, 2025  |  accessnewswire.comA
FINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit
March 4, 2025  |  accessnewswire.comA
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
March 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investors-who-lost-money-on-revance-therapeutics-incrvnc-should-contact-levi--korsinsky-about-pending-class-action---rvnc-302390881.html
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC
March 3, 2025  |  accessnewswire.comA
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
March 3, 2025  |  accessnewswire.comA
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC
March 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/03/3036116/673/en/rvnc-deadline-tomorrow-rosen-national-investor-counsel-encourages-revance-therapeutics-inc-investors-to-secure-counsel-before-important-march-4-deadline-in-securities-class-action-.html
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & Korsinsky
March 3, 2025  |  accessnewswire.comA
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
March 3, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250303520006/en/Deadline-Soon-Revance-Therapeutics-Inc.-RVNC-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz-About-Securities-Fraud-Lawsuit/
Revance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNC
March 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/03/3035916/0/en/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$36.81 -0.62 (-1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$36.79 -0.02 (-0.05%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$36.31 -0.04 (-0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$36.32 +0.01 (+0.04%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$28.99 -1.16 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$28.96 -0.02 (-0.09%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas